35.24
0.90%
-0.32
Pre-market:
37.00
1.76
+4.99%
Tandem Diabetes Care Inc stock is currently priced at $35.24, with a 24-hour trading volume of 747.51K.
It has seen a -0.90% decreased in the last 24 hours and a +4.60% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $35.58 pivot point. If it approaches the $34.89 support level, significant changes may occur.
Previous Close:
$35.56
Open:
$35.33
24h Volume:
747.51K
Market Cap:
$2.28B
Revenue:
$747.72M
Net Income/Loss:
$-222.61M
P/E Ratio:
-10.91
EPS:
-3.23
Net Cash Flow:
$-83.41M
1W Performance:
+15.81%
1M Performance:
+4.60%
6M Performance:
+96.00%
1Y Performance:
-6.03%
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Name
Tandem Diabetes Care Inc
Sector
Industry
Phone
858-366-6900
Address
11045 Roselle Street, San Diego, CA
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-04-23 | Downgrade | Citigroup | Buy → Neutral |
May-05-23 | Downgrade | BofA Securities | Neutral → Underperform |
Apr-24-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
Mar-29-23 | Initiated | UBS | Neutral |
Jan-26-23 | Initiated | Wolfe Research | Peer Perform |
Nov-15-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
Oct-18-22 | Initiated | Barclays | Overweight |
Oct-12-22 | Initiated | Jefferies | Buy |
Aug-09-22 | Downgrade | Wells Fargo | Overweight → Underweight |
Mar-02-22 | Resumed | BofA Securities | Neutral |
Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Jul-21-21 | Resumed | Cowen | Outperform |
May-25-21 | Initiated | Barclays | Underweight |
Dec-15-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Aug-20-20 | Initiated | Wells Fargo | Overweight |
Jul-31-20 | Upgrade | Guggenheim | Neutral → Buy |
Jul-06-20 | Upgrade | Citigroup | Neutral → Buy |
Jun-18-20 | Reiterated | Raymond James | Outperform |
Apr-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Mar-23-20 | Downgrade | Guggenheim | Buy → Neutral |
Mar-05-20 | Initiated | Citigroup | Neutral |
Feb-06-20 | Initiated | Raymond James | Outperform |
Feb-04-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
Oct-18-19 | Initiated | Guggenheim | Buy |
Oct-04-19 | Upgrade | UBS | Neutral → Buy |
May-17-19 | Reiterated | BofA/Merrill | Neutral |
May-13-19 | Initiated | SVB Leerink | Outperform |
Mar-08-19 | Initiated | BMO Capital Markets | Outperform |
Mar-05-19 | Reiterated | BofA/Merrill | Neutral |
Feb-27-19 | Reiterated | Lake Street | Buy |
Nov-21-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
Sep-26-18 | Reiterated | Dougherty & Company | Buy |
Sep-26-18 | Reiterated | Piper Jaffray | Overweight |
View All
Tandem Diabetes Care Inc Stock (TNDM) Latest News
Earnings Preview: Tandem Diabetes Care, Inc. (TNDM) Q1 Earnings Expected to Decline
Zacks Investment Research
Cracking The Code: Understanding Analyst Reviews For Tandem Diabetes Care
Benzinga
1 Beaten-Down Stock That Could Make You Richer
The Motley Fool
What 4 Analyst Ratings Have To Say About Tandem Diabetes Care
Benzinga
Tandem Diabetes (TNDM) Gains From Innovation Amid Macro Issues
Zacks Investment Research
Inari Medical (NARI) Up 4% Since Last Earnings Report: Can It Continue?
Zacks Investment Research
Tandem Diabetes Care Inc Stock (TNDM) Financials Data
Tandem Diabetes Care Inc (TNDM) Revenue 2024
TNDM reported a revenue (TTM) of $747.72 million for the quarter ending December 31, 2023, a -6.68% decline year-over-year.
Tandem Diabetes Care Inc (TNDM) Net Income 2024
TNDM net income (TTM) was -$222.61 million for the quarter ending December 31, 2023, a -135.33% decrease year-over-year.
Tandem Diabetes Care Inc (TNDM) Cash Flow 2024
TNDM recorded a free cash flow (TTM) of -$83.41 million for the quarter ending December 31, 2023, a -1,210% decrease year-over-year.
Tandem Diabetes Care Inc (TNDM) Earnings per Share 2024
TNDM earnings per share (TTM) was -$3.44 for the quarter ending December 31, 2023, a -132.43% decline year-over-year.
About Tandem Diabetes Care Inc
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:flex insulin delivery system that includes t:flex pump, its 480-unit disposable insulin cartridge, and an infusion set; t:slim X2 with G5 integration; and Tandem Device Updater, a PC and Mac-compatible tool that allows users to update their pump's software. In addition, the company offers t:connect diabetes management application, a cloud-based data management application, which provides a visual way to display therapy management data from the pump and supported blood glucose meters for users, their caregivers, and their healthcare providers; t:lock cartridge and infusion set products; and various pump accessories. Its products in development include automated insulin delivery systems; t:slim X2 with Basal IQ; t:slim X2 with control IQ; t:sport insulin delivery system; and connected (mobile) health mobile application. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was founded in 2006 and is headquartered in San Diego, California.
Cap:
|
Volume (24h):